Area of research
Statistics and Probability · Economics and Econometrics
Research interest
Research focused on Hazard ratio and Survival analysis, with related work in Inference, Nivolumab, Discontinuation. Notable publications include 'On the Restricted Mean Survival Time Curve in Survival Analysis', 'Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio', and 'Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies'.
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer
Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio
On the Restricted Mean Survival Time Curve in Survival Analysis
Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies